# OnCo record papillary-thyroid-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/papillary-thyroid-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "papillary-thyroid-cancer" ;
  schema:name "Papillary thyroid cancer"@en ;
  schema:alternateName "Papillary thyroid carcinoma"@en, "PTC"@en, "Papillary microcarcinoma (under 1 cm)"@en ;
  schema:description "Papillary thyroid cancer is the commonest and most curable thyroid cancer. Most people are treated with surgery, some with radioactive iodine afterwards, and many small tumours can simply be watched. Only the rare tumours that stop taking up iodine need targeted drugs."@en ;
  schema:url <https://onco.cc/cancers/papillary-thyroid-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Papillary_thyroid_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Papillary_thyroid_cancer>, <https://www.thyroid.org/professionals/ata-professional-guidelines/> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/anaplastic-thyroid-cancer/>, <https://onco.cc/cancers/follicular-thyroid-cancer/>, <https://onco.cc/cancers/medullary-thyroid-cancer/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ata-2015-thyroid-nodules-dtc-haugen-thyroid-2016/>, <https://onco.cc/key-papers/paper-select-lenvatinib-nejm-2015/>, <https://onco.cc/key-papers/paper-estimabl2-leboulleux-nejm-2022/>, <https://onco.cc/key-papers/paper-ito-kuma-active-surveillance-microcarcinoma-thyroid-2014/> ;
  onco:pipeline <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/larotrectinib/> ;
  onco:standardOfCare <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/cancers/thyroid/>, <https://onco.cc/technologies/radioiodine-therapy/>, <https://onco.cc/targets/tshr/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/terms/rai-refractory/> .